Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of ...

Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.

RUNX1 and SF3B1 mutations significantly impact overall survival and progression to acute myeloid leukemia ... in low-risk myelodysplastic neoplasms. Conventional parameters for risk stratification ...

Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes ...

INCB057643 Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study ...

for Myeloid Neoplasms.” The session will highlight the utility of myeloid comprehensive genomic profiling across a broad spectrum of categories, including acute myeloid leukemia, where rapid ...

Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Dr. Cecilia Yeung’s research focuses on genomic changes, clonal evolution, and epigenetic control of gene expression in myeloid neoplasms (MDS, MPN and AML) and she has developed research expertise in ...

The models were tested in the context of myeloproliferative neoplasms, a group of chronic ... transformation to acute myeloid leukemia and myelodysplastic syndromes. In her thesis, doctoral ...